Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
EDP-235
ENANTA PHARMACEUTICALS INC
COVID-19
3 trials -
EDP-305 1 mg
ENANTA PHARMACEUTICALS INC
Primary Biliary Cholangitis
1 trial -
EDP-305 1.5 mg
ENANTA PHARMACEUTICALS INC
Non-Alcoholic Steatohepatitis
1 trial -
EDP-305 Dose 1
ENANTA PHARMACEUTICALS INC
Non-Alcoholic Steatohepatitis
1 trial -
EDP-323 Dose Regimen 1
ENANTA PHARMACEUTICALS INC
RSV Infection
1 trial -
EDP-420 / Duration of Treatment - 3 days
ENANTA PHARMACEUTICALS INC
Community Acquired Pneumonia
1 trial -
EDP-938
ENANTA PHARMACEUTICALS INC
Respiratory Syncytial Virus (RSV)
2 trials -
EDP-938
ENANTA PHARMACEUTICALS INC
Respiratory Syncytial Virus Infections
1 trial -
EDP-938
ENANTA PHARMACEUTICALS INC
Respiratory Syncytial Virus
1 trial -
EDP-938
ENANTA PHARMACEUTICALS INC
RSV Infection
6 trials -
EDP-938 Dose 1
ENANTA PHARMACEUTICALS INC
RSV Infection
1 trial -
EDP-938, EDP-938 Placebo tablets
ENANTA PHARMACEUTICALS INC
Respiratory syncytial virus (RSV)
1 trial -
zelicapavir
ENANTA PHARMACEUTICALS INC
RSV Infection
1 trial -
DEB025
ENANTA PHARMACEUTICALS INC
Hepatitis C Virus
1 trial -
EDP 305
ENANTA PHARMACEUTICALS INC
Presumptive NAFLD
1 trial -
EDP 305
ENANTA PHARMACEUTICALS INC
NASH
1 trial -
EDP-235
ENANTA PHARMACEUTICALS INC
SARS CoV 2 Infection
1 trial -
EDP-297
ENANTA PHARMACEUTICALS INC
NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis
1 trial -
EDP-305
ENANTA PHARMACEUTICALS INC
NASH - Nonalcoholic Steatohepatitis
2 trials -
EDP-322
ENANTA PHARMACEUTICALS INC
MRSA, SSTI
1 trial -
EDP-322
ENANTA PHARMACEUTICALS INC
Skin and Soft Tissue Infections
1 trial -
EDP-323
ENANTA PHARMACEUTICALS INC
RSV Infection
3 trials -
EDP-494
ENANTA PHARMACEUTICALS INC
Hepatitis C
1 trial -
EDP-514
ENANTA PHARMACEUTICALS INC
Hepatitis B
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources